Using Farnesyltransferase Inhibitors to Reduce Inflammation in Thyroid Cancer
Author Information
Author(s): Katharine C DeGeorge, Brent R DeGeorge Jr, James S Testa, Jay L Rothstein
Primary Institution: Thomas Jefferson University
Hypothesis
Can farnesyltransferase inhibitors (FTI) inhibit the inflammatory activities of the RET/PTC3 oncogene?
Conclusion
Farnesyltransferase inhibitors may effectively reduce pro-inflammatory mediators induced by the RET/PTC3 oncogene in thyroid cells.
Supporting Evidence
- FTI treatment led to significant reductions in the expression of pro-inflammatory chemokines Ccl2 and Cxcl1.
- FTI did not affect the expression or apoptosis of RET/PTC3 itself.
- FTI showed effectiveness at nanomolar concentrations.
Takeaway
This study found that a drug called farnesyltransferase inhibitor can help reduce inflammation caused by a cancer gene in thyroid cells.
Methodology
In vitro assays were conducted using rat thyrocytes transfected with RET/PTC3 to measure the effects of FTI on chemokine expression and secretion.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Statistical Information
P-Value
<0.05
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website